NIAID

Investigators in the Division of Allergy, Pulmonary and Critical Care Medicine recently received a $4.5 million Asthma and Allergic Diseases Cooperative Research Center (AADCRC) grant from the National Institutes of Allergy and Infectious Diseases (NIAID). Read More

A number of factors during infancy increase the risk that a child will later develop asthma. Read More

New findings identify isoketal-modified proteins as a previously unrecognized feature of pulmonary fibrosis and as a potential therapeutic target for this disease. Read More

New structural details of the binding of the bacterium Streptococcus sanguinis to platelets may offer new therapeutics for life-threatening cardiovascular infections. Read More

Vanderbilt researchers show that a certain factor negatively impacts the first-line responder cells in the lungs, providing one explanation for why patients with asthma are at greater risk for invasive bacterial disease. Read More

James Crowe Jr., M.D., director of the Vanderbilt Vaccine Center, and Anthony Fauci, M.D., director of the National Institute of Allergy and Infectious Diseases (NIAID), recently participated in a U.S. Senate National Institutes of Health (NIH) caucus briefing held in Washington, D.C., by Senate NIH caucus co-chairs Sens. Lindsey Graham (R-SC) and Dick Durbin (D-IL). Read More

Vanderbilt investigators have discovered how human antibodies induced during testing of an experimental “bird flu” vaccine kill the virus. Read More

Vanderbilt University investigators have identified a cellular receptor for a toxin from Clostridium difficile (“C. diff”) — the leading cause of hospital-acquired diarrhea in the United States. Read More

Vanderbilt researchers have discovered that profound defects exist in the integrity of structural RNA molecules in patients with relapsing remitting multiple sclerosis. Read More

A series of experimental antibiotics may be a good starting point for developing new anticancer drugs. Read More

Understanding the role that host membrane modification plays in coronavirus replication is essential for developing novel approaches to block the viruses that cause SARS and MERS. Read More

New findings underscore the attractiveness of the HIV capsid – the structure that encloses the viral genome – as a therapeutic target. Read More

New studies explain how T-cell receptors use force to recognize and protect us against pathogens. Read More

New structural findings reveal how "gatekeeper" proteins participate in the secretion systems bacteria use to infect host cells. Read More

Antibiotic-resistant bacteria can share resources to cause chronic infections, Vanderbilt investigators have discovered. The findings shed light on a long-standing question in infectious diseases and may inform new treatment strategies. Read More

Compounds developed at Vanderbilt University may offer a new way to block influenza infection. Read More

Understanding how the immune system responds to the respiratory virus HMPV is crucial for developing vaccines and anti-viral treatments. Read More

A newly identified receptor allows mammalian reovirus to infect neurons, shedding light on factors important for viral encephalitis. Read More

Virus-like particles containing a protein from human metapneumovirus are a promising vaccine candidate for this respiratory virus. Read More

Understanding how chikungunya virus binds to and enters cells offers a new target for antiviral medications. Read More